Advancing precision oncology through systematic germline and tumor genetic analysis: The oncogenetic point of view on findings from a prospective multicenter clinical trial of 666 patients.

Fiche publication

Date publication

septembre 2023

Journal

Cancer medicine

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BINQUET Christine , Dr BOIDOT Romain , Pr GHIRINGHELLI François , Dr LANCON Allan , Pr FAIVRE Laurence , Dr FAVIER Laure , Dr NAMBOT Sophie , Dr DERANGERE Valentin , Dr MAZEL Benoît , Dr REDA Manon , Dr ALBUISSON Juliette , Dr GOUSSOT Vincent

Tous les auteurs :
Mazel B, Bertolone G, Baurand A, Cosset E, Sawka C, Robert M, Gautier E, Lançon A, Réda M, Favier L, Dérangère V, Richard C, Binquet C, Boidot R, Goussot V, Albuisson J, Ghiringhelli F, Faivre L, Nambot S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37694493

Résumé

With the emergence of targeted therapies, there is a need to accurately identify more tumor biomarkers. The EXOMA trial was designed to offer tumor and germline exome sequencing (ES) to patients with solid malignant tumors and facing therapeutic failure. As hereditary cancer predispositions could be identified, with genetic counseling and health management implications, a genetic consultation was systematically established. This design needs to be discussed as genetic human resources are limited and indication of theranostic tests will increase.